British Society for Haematology. Listening. Learning. Leading British Society for Haematology. Listening. Learning. Leading
22 July 2019

 

The latest figures on the size of the market for haemophilia A and B drugs suggest it will grow by more than 30% to reach $9.3 billion by 2028.

These figures have been calculated by the data analytics company GlobalData and published in their latest report ‘Hemophilia A and B: Global Drug Forecast and Market Analysis to 2028’. They explain that the bulk of this growth will come from alternative coagulation promoters and gene therapies.

Revenue is currently at $7.0 billion across the eight major markets of the USA, France, Germany, Italy, Spain, UK, Japan and China. At present, almost all sales are for plasma-derived replacement factors, the standard of care.

However, GlobalData analysts estimate the market will rise to $9.3 billion by 2028 - a growth rate of 3% per year. They predict that the share of the total sales held by replacement factors will fall from 97% today to 70% by 2028, with the rise of alternative coagulation promoters and gene therapies.

Dr Tajekesa Chapman, senior oncology and haematology analyst at GlobalData, explains: “Alternative Coagulation Promoters and gene therapies are the most anticipated drug classes for the treatment of haemophilia A and B as they will provide more effective treatments for patients with inhibitors, more convenient administration routes and less frequent dosing, and, in the case of gene therapies, provide a potential cure for the disease.”

Key opinion leaders interviewed by GlobalData in the eight major markets are highly optimistic about these therapies and agree that they will drive change in the treatment landscapes for haemophilia A and B.

Two major alternative coagulation promoters are likely to be Roche’s Hemlibra for haemophilia A, and Alnylam’s late-stage fitusiran for haemophilia A and B patients.

Dr Chapman adds: “Gene therapies are positioned for a limited patient population, such as severe adult haemophiliacs, previously treated patients, and patients with no history of inhibitors, and questions have already been raised about their limited long-term safety and efficacy data. Therefore, first-to-market advantage will drive commercial success.”

However, the report pinpoints a lack of long-term safety and efficacy data, and the high cost of gene therapies targeting a small patient population as a challenge to market access of these haemophilia A and B therapies.


Source: GlobalData

GlobalData (2019) “Hemophilia A and B – Epidemiology Forecast to 2028

GlobalData (2019) “Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

 

Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/